3 Stocks Pushing The Health Care Sector Lower

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 11 points (0.1%) at 16,218 as of Tuesday, Feb. 25, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,600 issues advancing vs. 1,298 declining with 186 unchanged.

The Health Care sector currently sits up 0.6% versus the S&P 500, which is up 0.2%. On the negative front, top decliners within the sector include Humana ( HUM), down 1.9%, and UnitedHealth Group ( UNH), down 0.8%. Top gainers within the sector include InterMune ( ITMN), up 159.0%, Grifols ( GRFS), up 3.0% and Boston Scientific ( BSX), up 2.2%.

TheStreet would like to highlight 3 stocks pushing the sector lower today:

3. Fresenius Medical Care AG & Co. KGaA ( FMS) is one of the companies pushing the Health Care sector lower today. As of noon trading, Fresenius Medical Care AG & Co. KGaA is down $1.96 (-5.4%) to $34.32 on heavy volume. Thus far, 200,033 shares of Fresenius Medical Care AG & Co. KGaA exchanged hands as compared to its average daily volume of 156,000 shares. The stock has ranged in price between $34.20-$34.61 after having opened the day at $34.44 as compared to the previous trading day's close of $36.28.

Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, operates in the field of dialysis care and dialysis products for the treatment of end-stage renal disease. Fresenius Medical Care AG & Co. KGaA has a market cap of $21.7 billion and is part of the health services industry. Shares are up 2.0% year-to-date as of the close of trading on Monday. Currently there are 2 analysts that rate Fresenius Medical Care AG & Co. KGaA a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Fresenius Medical Care AG & Co. KGaA as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations, increase in net income, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Fresenius Medical Care AG & Co. KGaA Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Tenet Healthcare ( THC) is down $3.84 (-8.0%) to $44.49 on heavy volume. Thus far, 3.8 million shares of Tenet Healthcare exchanged hands as compared to its average daily volume of 1.7 million shares. The stock has ranged in price between $44.07-$46.84 after having opened the day at $46.26 as compared to the previous trading day's close of $48.33.

Tenet Healthcare Corporation, an investor-owned health care services company, owns and operates acute care hospitals, ambulatory surgery centers, diagnostic imaging centers, urgent care centers, and related health care facilities in the United States. Tenet Healthcare has a market cap of $4.7 billion and is part of the health services industry. Shares are up 14.7% year-to-date as of the close of trading on Monday. Currently there are 7 analysts that rate Tenet Healthcare a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Tenet Healthcare as a hold. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year, growth in earnings per share and revenue growth. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, generally higher debt management risk and disappointing return on equity. Get the full Tenet Healthcare Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Regeneron Pharmaceuticals ( REGN) is down $7.33 (-2.1%) to $340.29 on average volume. Thus far, 559,376 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 902,100 shares. The stock has ranged in price between $337.27-$347.78 after having opened the day at $346.44 as compared to the previous trading day's close of $347.62.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $32.8 billion and is part of the drugs industry. Shares are up 26.3% year-to-date as of the close of trading on Monday. Currently there are 9 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income and feeble growth in the company's earnings per share. Get the full Regeneron Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).
null

If you liked this article you might like

Mining and Resources Lead Europe's Benchmarks Lower

Mining and Resources Lead Europe's Benchmarks Lower

European Stocks Diverge as Investors Weigh Economic Optimism With Mixed Earnings

European Stocks Diverge as Investors Weigh Economic Optimism With Mixed Earnings

Wednesday's Earnings Push Stocks Lower as Mood Sours in Europe

Wednesday's Earnings Push Stocks Lower as Mood Sours in Europe

Here's What's Boosting European Benchmarks

Here's What's Boosting European Benchmarks

Drug Price Inflation and a Patent Cliff Could Trigger a Wave of Deals in Generic Drugs Space

Drug Price Inflation and a Patent Cliff Could Trigger a Wave of Deals in Generic Drugs Space